Delving into the Latest Updates on ALDOS inhibitors(Daiichi Sankyo) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

CYP11B2

Action

inhibitors

Mechanism

CYP11B2 inhibitors(Cytochrome P450 11B2 inhibitors)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization-

Active Organization

Daiichi Sankyo Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

4-[(5-[2-Methyl-5-(methylsulfonyl)pentan-2-yl]sulfonylpyrimidin-4-yl)amino]benzonitrile 2 was identified as a novel potent aldosterone synthase inhibitor. Compound 2 was found to inhibit human CYP11B2 in the nanomolar range, and showed an aldosterone-lowering effect in a furosemide-treated cynomolgus monkey model. Although human CYP11B2 has the high homology sequence with human CYP11B1, compound 2 showed more than 80 times higher selectivity over human CYP11B1 in vitro.

100 Deals associated with ALDOS inhibitors(Daiichi Sankyo)

Login to view more data